Study reveals how uncertainty about cancer drugs influences patient decisions

NCT ID NCT07110597

Completed Knowledge-focused Sponsor: London School of Economics and Political Science Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study surveyed over 3,000 US adults to see how explaining different types of uncertainty about a new cancer drug (like whether it works for all races or has unknown side effects) affects people's willingness to take it. Participants read short statements about what is unknown and then rated how likely they would be to try the drug. The goal was to learn how to communicate uncertainty clearly without confusing or misleading patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors and regulators communicate the limits of what is known about new cancer drugs more clearly to patients.
What could go wrong: This is a survey, not a treatment trial. It measures hypothetical decisions, not real-world outcomes, so its impact on actual patient care is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER

Contacts and locations

Locations

London School of Economics and Political Science

London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.